3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Conditions
Breast Neoplasms
4
Head and Neck Neoplasms
3
Polycystic Ovary Syndrome
2
Pain
2
Neoplasms
2
Endocrine System Diseases
2
Amenorrhea
2
Trismus
1
Thrombosis
1
Neuroma
1
Movement Disorders
1
Motor Activity
1
Lymphedema
1
Health Education
1
Fibrosis
1
Deglutition Disorders
1
Anxiety Disorders
1
Agnosia
1
Interventions
Gemcitabine
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
parathyroid hormone-related peptide (1-36)
2
niraparib
2
Ocoxin
2
Musculoskeletal Manipulations
2
Metformin
2
Clomiphene
2
Cisplatin
2
repotrectinib
1
relacorilant
1
pralsetinib
1
pembrolizumab
1
napabucasin
1
fluorodopa F 18
1
anlotinib
1
adrenosterone
1
Thalidomide
1
Sunitinib
1
Spironolactone
1
Parathyroid Hormone-Related Protein
1
Parathyroid Hormone
1
Paclitaxel
1
Octreotide
1
Melphalan
1
Leuprolide
1
Irinotecan
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Endocrine System Diseases
×
Musculoskeletal Manipulations
×
Clear all
NCT00744510
2012-12-04
REPOS
University of Nottingham
Phase 3
Unknown
140 enrolled
NCT00746148
2012-12-04
REPOS
University of Nottingham
Phase 3
Unknown
140 enrolled